Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin

References

• Asghar U, Meyer T. (2012). Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56:1743–95.
   Web of Science ®Google Scholar
• Bao MH, Wong CC. (2021). Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells 10:1715.
   PubMed Web of Science ®Google Scholar
• Bar-Zeev M, Livney YD, Assaraf YG. (2017). Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance. Drug Resist Updat 31:15–30.
   PubMed Web of Science ®Google Scholar
• Bi QC, Luo RG, Li YS, et al. (2022). Low inorganic phosphate stress inhibits liver cancer progression: from in vivo to in vitro. Adv Ther 5:2100224.
   Web of Science ®Google Scholar
• Brown RB, Razzaque MS. (2016). Phosphate toxicity: a stealth biochemical stress factor? Med Mol Morphol 49:1–4.
   PubMed Web of Science ®Google Scholar
• Brown RB, Razzaque MS. (2018). Phosphate toxicity and tumorigenesis. Biochim Biophys Acta Rev Cancer 1869:303–9.
   PubMed Web of Science ®Google Scholar
• Chouhan S, Singh S, Athavale D, et al. (2020). Sensitization of hepatocellular carcinoma cells towards doxorubicin and sorafenib is facilitated by glucose-dependent alterations in reactive oxygen species, P-glycoprotein and DKK4. J Biosci 45:97.
   PubMed Web of Science ®Google Scholar
• Cox J, Weinman S. (2016). Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol 3:57–9.
   PubMed Web of Science ®Google Scholar
• Ding Y, Niu W, Zhang T, et al. (2019). Levistolide A synergistically enhances doxorubicin-induced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway. Oncol Rep 41:1198–208.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Bellanti F, Villani R, et al. (2017). Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United European Gastroenterol J 5:511–8.
   PubMed Web of Science ®Google Scholar
• Gaba RC, Emmadi R, Parvinian A, Casadaban LC. (2016). Correlation of doxorubicin delivery and tumor necrosis after drug-eluting bead transarterial chemoembolization of rabbit VX2 liver tumors. Radiology 280:752–61.
   PubMed Web of Science ®Google Scholar
• Huang CC, Wu MC, Xu GW, et al. (1992). Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84:262–4.
   PubMed Web of Science ®Google Scholar
• Huang WC, Hsieh YL, Hung CM, et al. (2013). BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PLOS One 8:e83627.
   PubMed Web of Science ®Google Scholar
• Kim TH, Shin YJ, Won AJ, et al. (2014). Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 1840:615–25.
   PubMed Web of Science ®Google Scholar
• Korita PV, Wakai T, Shirai Y, et al. (2010). Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep 23:965–72.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–42.
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Tirona RG, Kim RB. (2003). Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2:685–98.
   PubMed Web of Science ®Google Scholar
• Lohitesh K, Chowdhury R, Mukherjee S. (2018). Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int 18:44.
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C, et al. (2007). Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25.
   PubMed Web of Science ®Google Scholar
• Marin JJ, Romero MR, Martinez-Becerra P, et al. (2009). Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours. Curr Mol Med 9:1108–29.
   PubMed Web of Science ®Google Scholar
• Marin JJG, Briz O, Herraez E, et al. (2018). Molecular bases of the poor response of liver cancer to chemotherapy. Clin Res Hepatol Gastroenterol 42:182–92.
   PubMed Web of Science ®Google Scholar
• Marin JJG, Macias RIR, Monte MJ, et al. (2020). Molecular bases of drug resistance in hepatocellular carcinoma. Cancers 12:1663.
   PubMed Web of Science ®Google Scholar
• Nies AT, Konig J, Pfannschmidt M, et al. (2001). Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 94:492–9.
   PubMed Web of Science ®Google Scholar
• Petrillo M, Patella F, Pesapane F, et al. (2018). Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments. Future Oncol 14:2957–67.
   PubMed Web of Science ®Google Scholar
• Pleguezuelo M, Marelli L, Misseri M, et al. (2008). TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 8:1623–41.
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. (2022). BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681–93.
   PubMed Web of Science ®Google Scholar
• Scudellari M. (2014). Drug development: try and try again. Nature 516:S4–S6.
   PubMed Web of Science ®Google Scholar
• Soini Y, Virkajärvi N, Raunio H, Pääkkö P. (1996). Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 49:470–3.
   PubMed Web of Science ®Google Scholar
• Song JE, Kim DY. (2017). Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol 9:808–14.
   PubMed Web of Science ®Google Scholar
• Sukowati CH, Rosso N, Pascut D, et al. (2012). Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol 12:160.
   PubMed Web of Science ®Google Scholar
• Tredan O, Galmarini CM, Patel K, Tannock IF. (2007). Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–54.
   PubMed Web of Science ®Google Scholar
• Tsochatzis EA, Fatourou E, O'Beirne J, et al. (2014). Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 20:3069–77.
   PubMed Web of Science ®Google Scholar
• Vander Borght S, Komuta M, Libbrecht L, et al. (2008). Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 28:1370–80.
   PubMed Web of Science ®Google Scholar
• Varela M, Real MI, Burrel M, et al. (2007). Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–81.
   PubMed Web of Science ®Google Scholar
• Wakamatsu T, Nakahashi Y, Hachimine D, et al. (2007). The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 31:1465–72.
   PubMed Web of Science ®Google Scholar
• Wang J, Xu W, Zhang N, et al. (2021). X-ray-responsive polypeptide nanogel for concurrent chemoradiotherapy. J Control Release 332:1–9.
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, et al. (2005). Enhanced intracellular uptake of sterically stabilized liposomal doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res 22:933–9.
   PubMed Web of Science ®Google Scholar
• Yeo W, Mok TS, Zee B, et al. (2005). A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532–8.
   PubMed Web of Science ®Google Scholar
• Zheng C, Li M, Ding J. (2021). Challenges and opportunities of nanomedicines in clinical translation. BIO Integ 2:57–60.
   Google Scholar
• Zheng LH, Bao YL, Wu Y, et al. (2008). Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett 272:102–9.
   PubMed Web of Science ®Google Scholar